Although cellular infiltration was not evident when treatment with an IRAP inhibitor commenced at 6 h post-stroke, delayed treatment still reduced infarct volume and improved functional outcome suggesting that the benefits of IRAP inhibition are multifactorial and may vary depending on the temporality of the ischemic cascade. The gene discussed is LNPEP; the disease is Stroke.